PCVXVaxcyte, Inc.

1. Oct 5, 2026Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal.Regulation FD disclosure · press release
2. Sep 3, 2026On August 31, 2026, Vaxcyte, Inc. (the “Company”) appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.Director or officer change · Form 8-K
3. Aug 5, 2026Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
4. Jul 15, 2026On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.Director or officer change · Form 8-K
5. Jun 23, 2026On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.Director or officer change · Form 8-K
6. May 6, 2026Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
7. Feb 24, 2026Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
8. Feb 24, 2026Sales Agreement On February 24, 2026, Vaxcyte, Inc. (“Vaxcyte”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Placement Agent”), pursuant to which the Company may sell shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of …Other event · Form 8-K
9. Feb 2, 2026Underwriting Agreement On January 29, 2026, Vaxcyte, Inc. (“Vaxcyte”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
10. Dec 19, 2025Amendments to Executive Change in Control and Severance Agreements On December 18, 2025, Vaxcyte, Inc. (the “Company”) amended existing Executive Change in Control and Severance Agreements (the “Severance Agreements”) with (i) Grant Pickering, Chief Executive Officer and member of the Company’s Board of Directors …Director or officer change · Form 8-K
11. Nov 4, 2025Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.